Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $26.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 150.28% year-over-year to $26.7 million; the TTM figure through Mar 2026 stood at $26.7 million (up 150.28% YoY), while the FY2025 annual figure was $476000.0, changed N/A from the prior year.
• Other Non-Current Liabilities was $26.7 million for Q1 2026 at Amneal Pharmaceuticals, up from $476000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $79.2 million in Q2 2022 to a low of $476000.0 in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $21.1 million across 5 years, with a median of $8.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities sank 98.91% in 2023, then jumped 150.28% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $5.9 million in 2022, then sank by 45.91% to $3.2 million in 2023, then surged by 255.29% to $11.4 million in 2024, then tumbled by 95.82% to $476000.0 in 2025, then soared by 5519.12% to $26.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $26.7 million (Q1 2026), $476000.0 (Q4 2025), and $482000.0 (Q3 2025), per Business Quant data.